AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
3.820
-0.350 (-8.39%)
At close: Jun 5, 2026, 4:00 PM EDT
3.750
-0.070 (-1.83%)
After-hours: Jun 5, 2026, 4:27 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,645,381
Market Cap
137.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Molecular Partners AG | 134 |
| Agenus | 81 |
| Connect Biopharma Holdings | 64 |
| Korro Bio | 49 |
| Corbus Pharmaceuticals Holdings | 36 |
| Jyong Biotech | 27 |
| Galectin Therapeutics | 9 |
ANTX News
- 1 day ago - AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 1 day ago - AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease - TheFly
- 1 day ago - AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
- 15 days ago - AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire
- 17 days ago - AN2 Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 22 days ago - AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink - TheFly
- 25 days ago - AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c) - TheFly
- 25 days ago - AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights - Business Wire